Cardium Appoints CMO to Lead Generx™ Development Program
News Jan 24, 2006
Cardium Therapeutics, Inc. has announced the appointment of Randall W. Moreadith, M.D., Ph.D. as Executive Vice President and Chief Medical Officer.
"We are very pleased to welcome Dr. Randall Moreadith to Cardium's executive management team," said Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics.
"He assumes a key leadership position in our company to accelerate the late-stage clinical development of our lead product candidate, Generx, and to seek out promising corporate development opportunities."
Dr. Moreadith added, "I am very excited about joining Cardium's talented team and look forward to contributing to its future growth and success."
Before joining Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. Previously, he was co-founder, President and Chief Operating Officer of ThromboGenics Ltd., and served as Principal Medical Officer of Quintiles, Inc. where he co-founded Quintiles' Cardiovascular Therapeutics Group.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE